Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
01 February 2022Website:
http://www.engene.comNext earnings report:
31 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 21:02:10 GMTDividend
Analysts recommendations
Institutional Ownership
ENGN Latest News
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Officer.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). Today, the Company announced preliminary data from 21.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the second quarter ended April 30, 2024, and provided a business update. “Our $200 million private placement in February positioned us well to execute our p.
What type of business is enGene Holdings?
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
What sector is enGene Holdings in?
enGene Holdings is in the Healthcare sector
What industry is enGene Holdings in?
enGene Holdings is in the Biotechnology industry
What country is enGene Holdings from?
enGene Holdings is headquartered in Canada
When did enGene Holdings go public?
enGene Holdings initial public offering (IPO) was on 01 February 2022
What is enGene Holdings website?
https://www.engene.com
Is enGene Holdings in the S&P 500?
No, enGene Holdings is not included in the S&P 500 index
Is enGene Holdings in the NASDAQ 100?
No, enGene Holdings is not included in the NASDAQ 100 index
Is enGene Holdings in the Dow Jones?
No, enGene Holdings is not included in the Dow Jones index
When was enGene Holdings the previous earnings report?
No data
When does enGene Holdings earnings report?
The next expected earnings date for enGene Holdings is 31 December 2024